Crystalline anti-human IL-12 antibodies 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
US2014017256 A1 2014-01-16 [US20140017256]US8940873 B2 2015-01-27 [US8940873] / 2014-01-162015-01-27
申请号/申请日
2013US-13762171 / 2013-02-07
发明人
BORHANI DAVID W;FRAUNHOFER WOLFGANG;KRAUSE HANS-JUERGEN;KOENIGSDORFER ANETTE;WINTER GERHARD;GOTTSCHALK STEFAN;
申请人
ABBVIE;
主分类号
IPC分类号
A61K-039/395C07K-016/00C07K-016/24C30B-007/00G01N-031/00
摘要
(US8940873) The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2007US-60920608 2007-03-29 2008US-12079434 2008-03-27 2012US-13396563 2012-02-14 2013US-13762171 2013-02-07
主权利要求
(US8940873) The invention claimed is: 1.  A crystal of an anti-human IL-12 antibody comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1, and wherein said crystal has a length of about 2-500 mu m. 2. The crystal according to claim 1, wherein the antibody is ABT-874. 3. A method for treating a mammal comprising the step of administering to the mammal an effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises: (a) a crystal of an anti-human IL-12 antibody according to claim 1, and (b) at least one pharmaceutical excipient, thereby treating said mammal. 4. A method for treating a mammal comprising the step of administering to the mammal an effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises: (a) a crystal of an anti-human IL-12 antibody according to claim 1, and (b) at least one pharmaceutical excipient, which embeds or encapsulates the crystal. 5. The method according to claim 3 or 4, wherein the composition has an antibody concentration greater than about 1 mg/ml. 6. The method according to claim 5, wherein the composition has an antibody concentration greater than about 200 mg/ml. 7. The method according to claim 3 or 4, wherein the composition comprises at least one carrier selected from the group consisting of a polymeric biodegradable carrier, a polymeric non-biodegradable carrier, an oil carrier, and a lipid carrier. 8. The method according to claim 7, wherein the polymeric carrier is a polymer selected from one or more of the group consisting of: poly (acrylic acid), poly (cyanoacrylates), poly (amino acids), poly (anhydrides), poly (depsipeptide), poly (esters), poly (lactic acid), poly (lactic-co-glycolic acid) or PLGA, poly (beta -hydroxybutryate), poly (caprolactone), poly (dioxanone); poly (ethylene glycol), poly (hydroxypropyl)methacrylamide, poly[(organo) phosphazene, poly (ortho esters), poly (vinyl alcohol), poly (vinylpyrrolidone), maleic anhydride alkyl vinyl ether copolymers, pluronic polyols, albumin, alginate, cellulose and cellulose derivatives, collagen, fibrin, gelatin, hyaluronic acid, oligosaccharides, glycaminoglycans, sulfated polysaccharides, blends and copolymers thereof. 9. The method according to claim 3 or 4, wherein the composition is an injectable liquid composition having an antibody concentration in the range of about 10 to about 400 mg/ml. 10. The method according to claim 3 or 4, wherein the composition is a crystal slurry composition having an antibody concentration greater than about 100 mg/ml. 11. The method according to claim 3 or 4, wherein the composition is administered by a parenteral route, an oral route, or by an injection. 12. A method of treating an IL-12-related disorder in a subject, which method comprises administering to said subject a therapeutically effective amount of a crystal of an anti-human IL-12 antibody, comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1, and wherein said crystal has a length of about 2-500 mu m, thereby treating said subject. 13. The method of claim 12, wherein the IL-12-related disorder is selected from the group consisting of rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, inflammatory bowel disease, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis, dermatitis scleroderma, atopic dermatitis, graft versus host disease, organ transplant rejection, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein purpurea, microscopic vasculitis of the kidneys, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia, infectious diseases, parasitic diseases, acquired immunodeficiency syndrome, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, malignancies, heart failure, myocardial infarction, Addison's disease, sporadic, polyglandular deficiency type I and polyglandular deficiency type II, Schmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, alopecia greata, seronegative arthopathy, arthropathy, Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy, enteropathic synovitis, chlamydia, yersinia and salmonella associated arthropathy, spondyloarthopathy, atheromatous disease/arteriosclerosis, atopic allergy, autoimmune bullous disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune haemolytic anaemia, Coombs positive haemolytic anaemia, acquired pernicious anaemia, juvenile pernicious anaemia, myalgic encephalitis/Royal Free Disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, cryptogenic autoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome, Acquired Immunodeficiency Related Diseases, Hepatitis C, common varied immunodeficiency (common variable hypogammaglobulinaemia), dilated cardiomyopathy, female infertility, ovarian failure, premature ovarian failure, fibrotic lung disease, cryptogenic fibrosing alveolitis, post-inflammatory interstitial lung disease, interstitial pneumonitis, connective tissue disease associated interstitial lung disease, mixed connective tissue disease associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis associated interstitial lung disease, systemic lupus erythematosus associated lung disease, dermatomyositis/polymyositis associated lung disease, Sjodgren's disease associated lung disease, ankylosing spondylitis associated lung disease, vasculitic diffuse lung disease, haemosiderosis associated lung disease, drug-induced interstitial lung disease, radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease, postinfectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycemia, type B insulin resistance with acanthosis nigricans, hypoparathyroidism, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, osteoarthrosis, primary sclerosing cholangitis, idiopathic leucopenia, autoimmune neutropenia, renal disease NOS, glomerulonephritides, microscopic vasulitis of the kidneys, lyme disease, discoid lupus erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sclerosis (all subtypes), insulin-dependent diabetes mellitus, sympathetic ophthalmia, pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Takayasu's disease/arteritis, autoimmune thrombocytopenia, idiopathic thrombocytopenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary myxoedema, phacogenic uveitis, primary vasculitis and vitiligo. 14. A method for treating a mammal comprising the step of administering to the mammal an effective amount of a crystal of an anti-human IL-12 antibody, comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1, and wherein said crystal has a length of about 2-500 mu m, thereby treating said mammal. 15. The method according to claim 14, wherein the crystal has a sword-like morphology. 16. The method according to claim 15, wherein the antibody is an IgG antibody. 17. The method according to claim 16, wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3 and an IgG4 antibody. 18. The method according to claim 17, wherein the antibody is an anti-human IL-12 antibody of the group IgG1. 19. The method according to claim 18, wherein the crystal is prepared from an isolated human antibody that dissociates from human IL-12 with a Kd of 1 * 10-10 M or less and a koff rate constant of 1 * 10-3 s-1 or less, both determined by surface plasmon resonance.
法律状态
(US8940873) LEGAL DETAILS FOR US2014017256  Actual or expected expiration date=2028-03-27    Legal state=ALIVE    Status=GRANTED     Event publication date=2013-02-07  Event code=US/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=US US13762171  Application date=2013-02-07  Standardized application number=2013US-13762171     Event publication date=2014-01-16  Event code=US/A1  Event type=Examination events  Application published  Publication country=US  Publication number=US2014017256  Publication stage Code=A1  Publication date=2014-01-16  Standardized publication number=US20140017256     Event publication date=2014-08-29  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment OWNER: ABBVIE INC., ILLINOIS  Effective date of the event=2012-08-01  ASSIGNMENT OF ASSIGNORS INTEREST ASSIGNOR:ABBOTT LABORATORIES REEL/FRAME:033635/0829     Event publication date=2014-08-29  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment OWNER: ABBOTT LABORATORIES, ILLINOIS ASSIGNMENT OF ASSIGNORS INTEREST ASSIGNORS:BORHANI, DAVID W. FRAUNHOFER, WOLFGANG KRAUSE, HANS-JUERGEN AND OTHERS SIGNING DATES FROM 20080506 TO 20080617 REEL/FRAME:033635/0759     Event publication date=2014-08-29  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment OWNER: LUDWIG-MAXIMILIANS UNIVERSITAET MUENCHEN, GERMANY ASSIGNMENT OF ASSIGNORS INTEREST ASSIGNORS:WINTER, GERHARD GOTTSCHALK, STEFAN SIGNING DATES FROM 20080520 TO 20080530 REEL/FRAME:033635/0777     Event publication date=2014-08-29  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment OWNER: ABBOTT GMBH & CO. KG, GERMANY  Effective date of the event=2008-06-10  ASSIGNMENT OF ASSIGNORS INTEREST ASSIGNOR:LUDWIG-MAXIMILIANS UNIVERSITAET MUENCHEN REEL/FRAME:033635/0793     Event publication date=2014-08-29  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment OWNER: ABBOTT LABORATORIES, ILLINOIS  Effective date of the event=2008-05-14  ASSIGNMENT OF ASSIGNORS INTEREST ASSIGNOR:ABBOTT GMBH & CO. KG REEL/FRAME:033635/0801     Event publication date=2015-01-27  Event code=US/B2  Event indicator=Pos  Event type=Event indicating In Force  Granted patent as second publication  Publication country=US  Publication number=US8940873  Publication stage Code=B2  Publication date=2015-01-27  Standardized publication number=US8940873     Event publication date=2015-05-26  Event code=US/CC  Event type=Corrections  Certificate of correction
专利类型码
A1B2
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部